Key facts
- It has raised $78.3M across 3 recorded rounds; the latest was Early Stage VC ($19.0M) in Dec 2019.
- Notable investors include Labcorp Venture Fund, Cadron Capital Partners, NewRoad Capital Partners, Bess Ventures and Advisory, Collaborative Capital (Missouri) — 11 tracked in total.
- NOWDiagnostics has filed 5 Form Ds with the SEC since 2014, most recently Dec 2019 ($19.0M sold to 18 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for NOWDiagnostics
Funding rounds
3 roundsAbout NOWDiagnostics
Developer of medical testing kits designed to offer diagnostic testing in less time. The company's devices help in conducting at-home and in-clinic diagnostic tests that facilitate the process of testing for common ailments such as food intolerance and allergies, diseases, and respiratory and chronic illnesses, enabling caregivers to conduct any immunological assay to be accurately performed on-site in a stupe using a tiny amount of capillary blood or saliva of the patient.
- Sector
- Healthcare
- HQ
- Springdale, AR, United States
- Founded
- 2013
- Employees
- 36
- Website
- nowdx.com/
- Ownership
- Privately Held (backing)
NOWDiagnostics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in NOWDiagnostics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on NOWDiagnostics in its N-PORT filings yet. We sweep new filings monthly.